EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19

NCT04822818 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Corona Virus Infection
SARS (Severe Acute Respiratory Syndrome)
Virus Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Respiratory Tract Infections
Respiratory Tract Diseases

Interventions

DRUG: BEVA+SOC
DRUG: SOC

Sponsor

Assistance Publique - Hôpitaux de Paris